View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 18, 2021

Gritstone and CEPI to develop Covid-19 vaccine programme for variants

As part of the agreement, CEPI and Gritstone will provide the validated vaccine to the COVAX Facility.

Gritstone bio has signed a funding agreement of up to $20.6m with the Coalition for Epidemic Preparedness Innovations (CEPI) to expedite the development of its CORAL Covid-19 vaccine programme focusing on South African markets initially.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

CORAL programme is a second-generation Covid-19 vaccine platform offering spike and other SARS-CoV-2 T cell epitopes for potentially broad and long-lasting protection against variants of the virus.

Chimpanzee adenovirus, self-amplifying messenger ribonucleic acid (mRNA) or both can be the delivery vectors used.

As per the deal, CEPI will provide funds to conduct a multi-arm Phase I clinical trial of the CORAL programme’s self-amplifying mRNA (SAM) vaccine in naïve, convalescent and human immunodeficiency virus-positive (HIV+) patients.

Furthermore, the funding will facilitate pre-clinical studies, scale-up and development of a formulation to offer a stable drug product.

The trial will analyse two different SAM vaccine constructs that act on both the spike protein and additional SARS-CoV-2 targets. These are made to induce strong B as well as T cell immune responses.

Gritstone noted that the trial is anticipated to commence before this year-end.

In addition, CEPI and Gritstone bio will make the vaccine candidate available to the COVAX Facility for purchase and supply, on validating safety and efficiency.

Gritstone bio co-founder, president and CEO Andrew Allen said: “Our unique approach combines our self-amplifying mRNA platform with a broad set of viral antigens beyond spike intended to drive robust and durable immune responses comprising both neutralising antibodies and CD8+ T cells.

“With this unique antigenic breadth, our CORAL vaccine may offer protection against emerging spike variants of SARS-CoV-2 that appear challenging for first-generation vaccines.”

Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), a Phase I trial is presently analysing the reactogenicity and immunogenicity of CORAL in healthy subjects and as a booster shot for already vaccinated people.

Additional Phase I studies sponsored and performed by Gritstone in some populations are expected to launch before the end of this year.

The company noted that these trials will evaluate four different vaccine candidates and determine optimal dosing and antigenic content for the CORAL programme in youngsters, elderly, already vaccinated and immunocompromised individuals.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology